Resultados de procura - Susanne M. Hooshmand
- Mostrando 1 - 7 Resultados de 7
-
1
-
2
<i>O</i> 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors por Matthew H. Kulke, Jason L. Hornick, Christine Frauenhoffer, Susanne M. Hooshmand, David P. Ryan, Peter C. Enzinger, Jeffrey A. Meyerhardt, Jeffrey W. Clark, Keith Stuart, Charles S. Fuchs, Mark Redston
Publicado 2008Artigo -
3
Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database por Monica Ter‐Minassian, Jennifer A. Chan, Susanne M. Hooshmand, Lauren K. Brais, Anastassia Daskalova, Rachel Heafield, Laurie Buchanan, Zhi Rong Qian, Charles S. Fuchs, Xihong Lin, David C. Christiani, Matthew H. Kulke
Publicado 2013Artigo -
4
Prognostic Significance of MTOR Pathway Component Expression in Neuroendocrine Tumors por Zhi Rong Qian, Monica Ter‐Minassian, Jennifer A. Chan, Yu Imamura, Susanne M. Hooshmand, Aya Kuchiba, Teppei Morikawa, Lauren K. Brais, Anastassia Daskalova, Rachel Heafield, Xihong Lin, David C. Christiani, Charles S. Fuchs, Shuji Ogino, Matthew H. Kulke
Publicado 2013Artigo -
5
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes por Penelope A. Bradbury, Matthew H. Kulke, Rebecca S. Heist, Wei Zhou, Clement Ma, Wei Xu, Ariela L. Marshall, Rihong Zhai, Susanne M. Hooshmand, Kofi Asomaning, Li Su, Frances A. Shepherd, Thomas J. Lynch, John C. Wain, David C. Christiani, Geoffrey Liu
Publicado 2009Artigo -
6
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer por John Souglakos, Juliet Philips, R Wang, Sheeba Marwah, M Silver, Maria Tzardi, Jamie Silver, Shuji Ogino, Susanne M. Hooshmand, E.L. Kwak, Ellen Freed, Jeffrey A. Meyerhardt, Zacharenia Saridaki, Vassilis Georgoulias, Dianne M. Finkelstein, Charles S. Fuchs, Matthew H. Kulke, Ramesh A. Shivdasani
Publicado 2009Artigo -
7
Somatic mutation of CDKN1B in small intestine neuroendocrine tumors por Joshua M. Francis, Adam Kieżun, Alex H. Ramos, Stefano Serra, Chandra Sekhar Pedamallu, Zhi Rong Qian, Michaela S. Banck, Rahul Kanwar, Amit Kulkarni, Anna Karpathakis, Veronica E. Manzo, Tanupriya Contractor, Juliet Philips, Elizabeth Nickerson, Nam Pho, Susanne M. Hooshmand, Lauren K. Brais, Michael S. Lawrence, Trevor J. Pugh, Aaron McKenna, Andrey Sivachenko, Kristian Cibulskis, Scott L. Carter, Akinyemi I. Ojesina, Samuel S. Freeman, Robert T. Jones, Douglas Voet, Gordon Saksena, Daniel Auclair, Robert C. Onofrio, Erica Shefler, Carrie Sougnez, Jonna Grimsby, Lisa Green, Niall J. Lennon, Tim Meyer, Martyn Caplin, Daniel C. Chung, Andreas S. Beutler, Shuji Ogino, Christina Thirlwell, Ramesh A. Shivdasani, L. Sylvia, Chris Harris, Gad Getz, Matthew H. Kulke, Matthew Meyerson
Publicado 2013Artigo
Ferramentas de procura:
Materias Relacionadas
Internal medicine
Medicine
Biology
Oncology
Immunohistochemistry
Neuroendocrine tumors
Cancer research
Chemotherapy
Confidence interval
Gene
Hazard ratio
Biochemistry
Cancer
Genetics
Adenocarcinoma
Allele
Biomarker
CA19-9
Case-control study
Cell biology
Cell cycle
Cetuximab
Chromogranin A
Cisplatin
Colorectal cancer
Computer science
Cyclin
Cyclin-dependent kinase 6
DNA
DNA repair